10x Genomics (NASDAQ:TXG) vs. Many Bright Ideas Technologies (OTCMKTS:MBGNF) Head to Head Survey

Many Bright Ideas Technologies (OTCMKTS:MBGNF – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Valuation & Earnings

This table compares Many Bright Ideas Technologies and 10x Genomics”s top-line revenue, earnings per share and valuation.

Many Bright Ideas Technologies has higher earnings, but lower revenue than 10x Genomics.

Institutional & Insider Ownership

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Many Bright Ideas Technologies and 10x Genomics’ net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Many Bright Ideas Technologies and 10x Genomics, as provided by MarketBeat.com.

10x Genomics has a consensus price target of $38.31, suggesting a potential downside of 37.75%. Given 10x Genomics’ stronger consensus rating and higher probable upside, analysts clearly believe 10x Genomics is more favorable than Many Bright Ideas Technologies.

Summary

10x Genomics beats Many Bright Ideas Technologies on 6 of the 9 factors compared between the two stocks.

About Many Bright Ideas Technologies

(Get Free Report)

Many Bright Ideas Technologies Inc. does not have significant operations. It was previously engaged in the life science business with a focus on the commercialization of prognostic genomic-based tests for non-small-cell lung cancer. It focuses on the commercialization of technologies in various industrial sectors. The company is headquartered in Vancouver, Canada.

About 10x Genomics

(Get Free Report)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.